A comparative study of the efficacy of ceftazidime versus cefazolin and tobramycin in patients with acute exacerbations of chronic bronchitis.

Fifty-nine adult patients have entered this study. The initial pathogens were eradicated from the infection sites and all except two of the patients who were assessed clinically in the ceftazidime group and 4 cases in the comparative group were cured or improved. No adverse reactions were connected to ceftazidime or to tobramycin and cefazolin.

Trial of ceftazidime efficacy in respiratory infections at two dose levels.

A dose-ranging clinical trial of ceftazidime was carried out in patients with respiratory infections. Patients were randomly allocated to receive either 500 mg or 1 g doses of ceftazidime twice-daily intravenously. The organisms isolated from sputum were eradicated in 23 cases, and in 18 cases within 3 days.

[Silicotuberculosis in Austria and the industrial injuries act (author's transl)].

The case material comprising all persons who developed silico-tuberculosis since it was listed as an occupational disease almost 50 years ago is analysed. The relationship between various occupations and the incidence of silicosis is reviewed with special reference to the most exposed group: the wokers in the granite quarries of Upper Austria. The changes in the clinical picture of the lesion, legal aspects, diagnostic difficulties in distinguishing between silicosis with or without complicating tuberculosis are discussed.